NextPoint Therapeutics raises $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. Existing investors that took part in the financing include MPM Capital Management and Dana-Farber Cancer Institute
Paragon Therapeutics, Inc. + Apogee Therapeutics, Inc.
Antibody Discovery and Option Agreement
Option for exclusive development and commercial rights to a suite of Paragon’s top-tier antibodies specifically engineered to target some of the largest and highest unmet needs in inflammatory and immunological conditions
CRO and Site Agreements for an Open-Label, Phase 2 Study with 30 Sites in 9 Countries exploring the efficiency of Neratinib on Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations Or EGFR Gene Amplification
Co-counsel to Vertex on acquisition of ViaCyte, a privately-held biotechnology company that received substantial research funding from the California Institute of Regenerative Medicine
Multi-year collaboration with AbCellera to discover therapeutic antibodies for multiple targets selected by Versant’s portfolio of biologics-focused biotechnology companies
Vernal Biosciences raises $21M Series A equity funding led by Dynamk Life Sciences Fund, L.P., Charles River Laboratories, Inc. and Ampersand 2020 Limited Partnership
Artax Biopharma, Inc. + Advent Life Sciences Fund II LP
Series B Financing (Series B4)
Artax Biopharma raises Series B-4 round of equity funding led by Advent Life Sciences Fund II LP, Advent Life Sciences LLP, Columbus Life Science Fund II, FCR, Hiyuli Ventures Limited, Belinda A. Termeer, and other existing investors, plus new investors including Sound Bioventures Fund I AB and and Eli Lilly
Dianthus raises $100 million Series A financing led by 5AM Ventures, Fidelity Management & Research Company, Avidity Partners, Venrock, Fairmount Funds, Tellus BioVentures and other investors
This site uses cookies. Some provide anonymous analysis of how our website is used and some are essential to make the website work. Other cookies enable personalized services or social media features to be used. By using our website, you agree to the use of cookies. To find out more, please see our Privacy Policy. You can disable cookies at any time by changing your browser settings.